[{"address1": "1065 East Hillsdale Boulevard", "address2": "Suite 100", "city": "Foster City", "state": "CA", "zip": "94404", "country": "United States", "phone": "650 525 5535", "fax": "650 275 4254", "website": "https://www.ternspharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.", "fullTimeEmployees": 66, "auditRisk": 3, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 2, "previousClose": 6.98, "open": 6.96, "dayLow": 6.85, "dayHigh": 7.31, "regularMarketPreviousClose": 6.98, "regularMarketOpen": 6.96, "regularMarketDayLow": 6.85, "regularMarketDayHigh": 7.31, "beta": -0.417, "forwardPE": -5.2773724, "volume": 1061825, "regularMarketVolume": 1061825, "averageVolume": 975006, "averageVolume10days": 1246890, "averageDailyVolume10Day": 1246890, "bid": 7.2, "ask": 7.24, "bidSize": 400, "askSize": 400, "marketCap": 467615424, "fiftyTwoWeekLow": 3.26, "fiftyTwoWeekHigh": 10.67, "fiftyDayAverage": 5.9872, "twoHundredDayAverage": 5.853075, "currency": "USD", "enterpriseValue": 227388752, "floatShares": 23587755, "sharesOutstanding": 64677100, "sharesShort": 2234303, "sharesShortPriorMonth": 4396453, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0345, "heldPercentInsiders": 0.01788, "heldPercentInstitutions": 1.19354, "shortRatio": 2.94, "shortPercentOfFloat": 0.0392, "impliedSharesOutstanding": 64677100, "bookValue": 3.661, "priceToBook": 1.9748702, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -91055000, "trailingEps": -1.26, "forwardEps": -1.37, "enterpriseToEbitda": -2.196, "52WeekChange": -0.24765867, "SandP52WeekChange": 0.26238096, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "TERN", "underlyingSymbol": "TERN", "shortName": "Terns Pharmaceuticals, Inc.", "longName": "Terns Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1612535400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "7e7e889b-1f93-38a3-8cbf-64bb942bfd16", "messageBoardId": "finmb_558294166", "gmtOffSetMilliseconds": -14400000, "currentPrice": 7.23, "targetHighPrice": 22.0, "targetLowPrice": 5.5, "targetMeanPrice": 14.21, "targetMedianPrice": 15.0, "recommendationMean": 2.1, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 240654000, "totalCashPerShare": 3.721, "ebitda": -103549000, "totalDebt": 427000, "quickRatio": 27.26, "currentRatio": 27.854, "debtToEquity": 0.18, "returnOnAssets": -0.23686, "returnOnEquity": -0.34727, "freeCashflow": -44619376, "operatingCashflow": -75806000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]